

# Diagnosis and management of depression in adolescents

Daphne J. Korczak MD MSc, Clara Westwell-Roper MD PhD, Roberto Sassi MD PhD

■ Cite as: *CMAJ* 2023 May 29;195:E739-46. doi: 10.1503/cmaj.220966

Depression is common, a leading cause of disability and a major contributor to the overall global burden of disease.<sup>1</sup> Although more than 40% of people with depression experience onset before adulthood, depression remains undetected in many adolescents in Canada, and most are untreated.<sup>2-4</sup> Clinicians consistently report a lack of confidence in their ability to care for adolescents with depression.<sup>5</sup> We review the diagnosis and management of depression in adolescents, drawing on available evidence and recommendations from international guidelines, as outlined in Box 1.

## What is the burden of depressive illness in adolescents?

The prevalence of depression among adolescents increases with age.<sup>4</sup> Before the COVID-19 pandemic, the prevalence of major depressive disorder (MDD) among adolescents was reported to be about 13%–15%.<sup>6,7</sup> A recent meta-analysis found that around 1 in 4 youth had clinically significant depressive symptoms during the COVID-19 pandemic, with higher rates associated with older age and female sex; it also found the prevalence of symptoms to be higher later during the pandemic period.<sup>8</sup>

The onset of depression before adulthood is associated with greater illness severity in adulthood (i.e., increased number of episodes, hospital admissions and risk of self-harm and suicide), poorer physical health outcomes (including obesity, diabetes and cardiovascular disease)<sup>9,10</sup> and social and occupational outcomes.

## What are the multifactorial drivers of depression?

Genetic and environmental factors interact with each other in complex pathways to increase risk of, or resilience to, depression among children and adolescents.<sup>11,12</sup> Family history of depression is associated with a three- to fivefold increased risk of depression among older children,<sup>13</sup> and genome-wide association studies have identified numerous loci correlated with MDD.<sup>12</sup> Several mechanisms can be involved in the intergenerational transmission of depression, including inheritance of

### Key points

- Depression is common among adolescents in Canada and has the potential to negatively affect long-term function and quality of life; despite this, in most affected adolescents depression remains undetected and untreated.
- Management requires a multimodal approach, including risk assessment, psychoeducation, psychotherapeutic and pharmacologic treatment, and interventions to address contributing factors.
- Support from child and adolescent psychiatrists may be required in the case of diagnostic uncertainty and complex presentations, as well as for patients who do not respond to first-line treatments.

### Box 1: Evidence used in this review

We conducted a targeted search of MEDLINE, PubMed and PsycINFO using keywords and subject headings for depression (“depress\*” or “dysthymia” or “mood disorder”; medical subject heading [MeSH] term “Depressive Disorder”) in children and adolescents (“youth\*”, “adolescen\*”, “child,” “pediatric,” “paediatric”; MeSH terms “Child,” “Child, Preschool” and “Adolescent”). The search included English-language studies involving humans, published from database inception to May 16, 2022. We identified additional sources by examining the references of relevant publications. We included systematic and narrative reviews, randomized controlled trials and cohort studies that addressed aspects of the diagnosis or management of major depressive disorder or persistent depressive disorder among children and adolescents aged 18 years or younger. We also reviewed relevant clinical practice guidelines from Canada, the United States, United Kingdom, Australia and New Zealand.

genes that are associated with psychological traits that may increase depression risk,<sup>14</sup> exposure to parental depression in the postnatal period,<sup>15</sup> adverse childhood experiences<sup>16</sup> and family conflict.<sup>17</sup> Stigma and experiences of bullying have been linked to increased rates of depression among LGBTQ2+ adolescents.<sup>18</sup> Data from the United States suggest that intersectionality between race and gender exacerbates depression.<sup>19</sup>

## How is depression diagnosed in children and adolescents?

Diagnostic criteria for MDD and persistent depressive disorder are summarized in Table 1. Compared with adults with depression, children and adolescents may be more likely to present with irritability and labile — rather than low — mood, somatic concerns and social withdrawal.<sup>21,22</sup> Onset of depression before adulthood may also be associated with atypical features such as hypersomnia and increased appetite.<sup>23</sup> Compared with younger children, adolescents are less likely to present with anxiety, somatic symptoms, psychomotor agitation and hallucinations.<sup>24,25</sup>

Risk assessment is a critical component of the assessment of depression and includes review of current suicidal ideation, intent and plan; recent hopelessness, perceived burdensomeness and impulsivity; previous suicide attempts and nonsuicidal self-injury; situational stressors; and protective factors, including supports and future orientation.<sup>2,26,27</sup> Validated scales such as the Columbia Suicide Severity Rating Scale may supplement clinical judgment.<sup>28,29</sup>

## Should clinicians screen for adolescent depression?

Although no direct evidence currently indicates that universal screening for MDD in primary care leads to improved outcomes,

indirect evidence suggests that treatment of MDD detected through screening is associated with moderate benefit.<sup>30</sup> The United States Preventive Services Task Force (USPSTF) and most clinical practice guidelines (Table 2) recommend screening for depression in primary care for young people aged 12–18 years. In 2005, the Canadian Task Force on Preventive Health Care recommended against routine screening for youth,<sup>39</sup> concluding that more research examining associated risks and benefits was needed; an updated guideline is pending.<sup>47</sup> Screening in this age group may be a reasonable approach, however, when implemented together with adequate systems that ensure accurate diagnosis and appropriate follow-up.<sup>30</sup>

Validated screening tools for adolescent depression are listed in Table 3. Consistent with USPSTF recommendations and guideline appraisal (Table 2),<sup>43</sup> we suggest use of the Patient Health Questionnaire-9 (PHQ-9), the PHQ modified for adolescents (PHQ-A), or the Center for Epidemiologic Studies Depression Scale for Children, all of which are in the public domain.<sup>54</sup> The PHQ-2 (which does not include items related to suicidality) may be appropriate for an initial remote screen, followed by a PHQ-9 in clinic if the initial screen is positive.<sup>34</sup> The same tools may be used for monitoring of treatment response. Further assessment of the patient is required for diagnosis. A collateral history from parents or others able to comment on core symptoms and functioning is helpful.<sup>55</sup> More general tools,

**Table 1: Summary of diagnostic criteria for major depressive disorder and persistent depressive disorder\***

Diagnosis	Criteria
Major depressive disorder	<p>Two weeks of a persistent change in mood that is either depressed or irritable, or persistent loss of interest or anhedonia, accompanied by at least 3 of the following symptoms of a major depressive episode, present most days:</p> <ul style="list-style-type: none"> <li>• weight loss (or failure to gain weight)</li> <li>• change in appetite</li> <li>• insomnia or hypersomnia</li> <li>• psychomotor retardation or agitation</li> <li>• fatigue or loss of energy</li> <li>• excessive or inappropriate guilt or feelings of worthlessness</li> <li>• indecisiveness or diminished ability to concentrate</li> <li>• recurrent thoughts of death or suicidal ideation</li> </ul> <p>These symptoms result in a change from previous functioning and are not attributable to substances, medications or other disorders.</p>
Persistent depressive disorder	<p>Episode of depressed or irritable mood that persists for at least 1 year, accompanied by at least 2 of the following symptoms, present most days:</p> <ul style="list-style-type: none"> <li>• hopelessness</li> <li>• insomnia or hypersomnia</li> <li>• hyperphagia or poor appetite</li> <li>• fatigue or low energy</li> <li>• low self-esteem</li> <li>• indecisiveness or poor concentration</li> </ul> <p>These symptoms result in a change from previous functioning and are not attributable to substances, medications or other disorders. There may or may not be associated intermittent or persistent major depressive episodes.</p>

\*Refer to *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision*<sup>20</sup> for full criteria.

such as the SSHADESS (strengths, school, home, activities, drugs and substance use, emotions, eating, and depression, sexuality and safety) interview,<sup>56</sup> can identify risk factors for mental health conditions, but are not validated as screening tools for psychiatric disorders.

Before assessment, clinicians should review confidentiality rules and limits with the patient and caregivers, emphasizing respect for autonomy and addressing any questions regarding sharing of or access to the patient's medical information. Limits to confidentiality should also be addressed, including situations in which the clinician would be obliged to share information with parents, guardians or other services. The patient and caregiver may be seen together initially and then separately, according to the adolescent's level of comfort. If a patient does not want the caregiver informed of specific details of the assessment, we suggest working collaboratively to understand barriers to disclosure

and ways to facilitate sharing of information that may help parents provide support. When safety concerns relevant to management are present and need to be shared with parents, the clinician should inform the young person and involve them in discussion about how this will be done.

### What differential diagnoses should be considered?

The differential diagnosis for MDD includes adjustment disorder with depressed mood, sadness or irritability related to situational stressors, persistent depressive disorder (without a history of major depressive episode) and bipolar disorder. Clinicians should consider whether substances and medications are contributing to the presentation. Demoralization and dysphoria can occur secondary to other mental or physical health disorders, or

**Table 2: Clinical practice guidelines addressing the assessment or management of depressive disorders among children and youth**

Organization	Guideline	Publication year*	AGREE-II score†
American Academy of Pediatrics	Guidelines for adolescent depression in primary care (GLAD-PC) – part I: practice preparation, identification, assessment and initial management <sup>31</sup>	2018	60‡
	Guidelines for adolescent depression in primary care (GLAD-PC) – part II: treatment and ongoing management <sup>32</sup>		
American Academy of Child and Adolescent Psychiatry	Practice parameter for the assessment and treatment of children and adolescents with depressive disorders <sup>33</sup>	2007	55
	Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders <sup>34</sup>	2022	NA
American Psychological Association	Clinical practice guideline for the treatment of depression across three age cohorts <sup>35</sup>	2019	67‡
Canadian Network for Mood and Anxiety Treatments	Clinical guidelines for the management of adults with major depressive disorder: section 6, special populations: youth, women and the elderly <sup>36</sup>	2016	60‡
Canadian Paediatric Society	Practice point on suicidal ideation and behaviour <sup>37</sup>	2015 (2019)	NA
	Position statement for the use of selective serotonin reuptake inhibitor medications for treatment of child and adolescent mental illness <sup>38</sup>	2013	NA
Canadian Task Force on Preventive Health Care	Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care <sup>39</sup>	2005	NA
National Institute for Health and Care Excellence	Guideline on depression in children and young people: Identification and management <sup>40</sup>	2019	72‡
Royal Australian and New Zealand College of Psychiatrists	Clinical practice guidelines for mood disorders <sup>41</sup>	2020	70‡
United States Preventive Service Task Force	Final Recommendation Statement: Depression in Children and Adolescents: Screening <sup>42</sup>	2016	48

Note: AGREE = Appraisal of Guidelines for Research and Evaluation, NA = not available.

\*Original date of publication, with date of update indicated in brackets, if applicable.

†See Yan and colleagues<sup>43</sup> for guideline appraisal using the AGREE II tool.<sup>44</sup>

‡Designated as "recommended" based on Agree-II score.<sup>45</sup> See Bennett and colleagues<sup>45</sup> for an appraisal of earlier versions of several practice guidelines and Duda and colleagues<sup>46</sup> for discussion of the role of critical appraisal of practice guidelines in child and youth mental health.

**Table 3: Validated screening tools for depression in children and youth\***

Screening tool	Age, yr	Forms	Access
Patient Health Questionnaire (PHQ)-9: Modified for Teens <sup>48</sup>	12–18	Self-report	Public domain; available from the GLAD-PC toolkit at <a href="http://gladpc.org/">http://gladpc.org/</a>
Center for Epidemiologic Studies Depression Scale for Children (CES-DC) <sup>49</sup>	≥ 6	Self-report	Public domain; available at <a href="https://www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/symptoms/ces_dc.pdf">https://www.aacap.org/App_Themes/AACAP/docs/member_resources/toolbox_for_clinical_practice_and_outcomes/symptoms/ces_dc.pdf</a>
Mood and Feelings Questionnaire <sup>50</sup>	6–19	Self-report	Copyrighted but free for noncommercial use; available at <a href="https://devepi.duhs.duke.edu/measures/the-mood-and-feelings-questionnaire-mfq/">https://devepi.duhs.duke.edu/measures/the-mood-and-feelings-questionnaire-mfq/</a>
		Parent-report	
Revised Children's Anxiety and Depression Scale <sup>51</sup>	8–18	Self-report	Copyrighted but free for noncommercial use; available at <a href="https://www.childfirst.ucla.edu/resources">https://www.childfirst.ucla.edu/resources</a>
		Parent-report	
Beck Depression Inventory <sup>52</sup>	≥ 13	Self-report	Available for purchase
Child Depression Inventory <sup>53</sup>	7–17	Self-report	Available for purchase
		Parent-report	
		Teacher-report	

\*A general list of mental health screening tools and rating scales can be accessed via the Canadian Paediatrics Society (<https://cps.ca/en/mental-health-screening-tools>).

to psychosocial factors. Bipolar disorder is often initially misidentified as unipolar MDD because the mood episode at onset is frequently a depressive one; it may also be challenging to elicit a history of subtle or short-duration hypomanic symptoms.<sup>36,57</sup> Further risk factors for bipolar disorder are listed in Table 4.

More than 60% of adolescents with MDD have at least 1 comorbid mental health diagnosis,<sup>2</sup> most commonly anxiety disorders, attention-deficit hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder and substance use disorders; others include eating disorders, learning disorders and somatic disorders.<sup>64</sup> Youth with chronic medical conditions including chronic pain, neurologic disorders and autoimmune or inflammatory diseases also have higher levels of comorbid depressive symptoms than healthy peers.<sup>56,65,66</sup> Among these youth, symptoms such as fatigue, decreased concentration, sleep and appetite disturbances may overlap with features of depression, making the diagnosis challenging; thoughts of guilt, hopelessness, worthlessness or suicidal ideation raise concern for MDD.<sup>67</sup> A bidirectional relationship is often found between comorbid psychiatric (e.g., ADHD, anxiety, learning disorders) and physical conditions and depression; pre-existing conditions are often predisposing factors for an eventual diagnosis of MDD. Moreover, MDD is frequently an independent risk factor for poor treatment response and increased morbidity of other chronic physical and psychiatric disorders.<sup>68</sup>

Physical health conditions may also mimic primary depressive disorder, including hypothyroidism, anemia, mononucleosis, traumatic brain injury and autoimmune disorders.<sup>33</sup> Physical examination, together with investigations such as complete blood count and thyroid-stimulating hormone levels, are often appropriate to rule out anemia and hypothyroidism. Further laboratory work-up, electrocardiography, electroencephalography and neuroimaging are not generally indicated but may be considered in some circumstances based on history and physical examination.

**Table 4: Clinical features of major depressive episodes that may raise the index of suspicion for underlying bipolar disorder and prompt specialist referral**

Type	Feature
Symptoms	Presence of mixed symptoms
	Mood lability
	Psychomotor retardation
	Delusions including pathological guilt
	Psychotic symptoms
Course	Catatonia
	Abrupt onset or offset
	Recurrent, shorter episodes
	Frequent episodes
	Treatment resistance
Family history	SSRI-induced mania
	Bipolar disorder
	Psychotic disorder
	Parental illness characteristics (e.g., age at onset, severity)
	Suicide

Note: SSRI = selective serotonin reuptake inhibitor. Refer to O'Donovan et al. for recent review of bipolar risk in depression,<sup>58</sup> with risk factors also compiled from recent studies.<sup>57,59–63</sup>

## How should depression be managed in adolescents?

A multimodal management plan for children and youth with depression begins with psychoeducation and may involve lifestyle management, psychotherapy and medication, in addition to addressing potential contributing factors. Symptom monitoring

during treatment using standardized, validated measures is encouraged (Table 3). Importantly, a suicide risk assessment must be done to ensure appropriateness of an outpatient management plan and facilitate safety planning.

Psychoeducation provides the adolescent and family with an understanding of the factors that may relate to the condition, the diagnosis and the anticipated course of treatment. A shared understanding is essential for engagement in treatment.<sup>2,69</sup> It can be helpful to caregivers even if the youth with depression is reluctant to engage in their own treatment, as these techniques can facilitate problem solving and family communication skills.<sup>34</sup>

### Lifestyle measures

Lifestyle interventions include strategies to improve physical activity, dietary patterns and sleep. Systematic reviews of observational studies have noted that unhealthy lifestyle factors are associated with increased depressive symptoms among children and adolescents.<sup>70</sup> Although lifestyle interventions have been endorsed by clinical practice guidelines, particularly with respect to the management of mild-to-moderate MDD, data are less robust than for adults with MDD.<sup>71</sup> Clinicians should exercise caution in overstating the effects of lifestyle interventions as standalone interventions for youth with moderate-to-severe MDD; however, given that effectiveness varies by individual, depressed adolescents frequently feel that they are to blame for their illness, and depressive symptoms (e.g., fatigue, anhedonia, appetite disturbance) are perpetuating factors for unhealthy lifestyles. Further research is needed to better characterize the optimal use of lifestyle interventions, the patient- and disease-specific factors most likely to respond to these strategies and the magnitude of the effect size that adolescents, families and clinicians can expect.

Regular moderate-to-vigorous physical activity has been shown to improve mood in youth.<sup>72,73</sup> Some studies suggest that even short durations of exercise may be effective.<sup>74</sup> The potential benefits of physical activity as standalone interventions are greater when depressive symptoms are mild to moderate in severity. An association between unhealthy dietary patterns and more severe depressive symptoms has been shown in observational studies.<sup>70,75</sup> Randomized controlled trials (RCTs) of dietary interventions for adults with MDD suggest that a diet lower in sugar-sweetened drinks, processed foods and meats, and higher in vegetables, fruit and legumes is associated with lower depressive symptoms.<sup>76</sup>

Bright light therapy has been evaluated in a few small trials involving young patients, and the results suggest a positive effect, particularly for seasonal depression.<sup>77</sup>

### Psychotherapy

Cognitive behavioural therapy (CBT) is the psychotherapy with the greatest evidence for efficacy in the treatment of adolescent depression.<sup>78,79</sup> This approach targets the cognitive distortions, negative intrusive thoughts and behavioural manifestations of depression, such as anhedonia and decreased motivation.<sup>34</sup> Adolescents with more severe depressive symptoms, poor coping skills and non-suicidal self-injury tend to have a less robust response to CBT.<sup>80</sup> Interpersonal therapy, in particular when designed for adolescents, has some evidence for efficacy.<sup>78,81</sup> Interpersonal therapy focuses on the role of interpersonal relationships in depression, aiming to

reduce interpersonal stress and improve social functioning.<sup>34</sup> A greater number of studies support CBT and interpersonal therapy delivered individually rather than in a group format.<sup>78</sup> Computer-based CBT or interpersonal therapy has been reported to be as effective as in-person administration,<sup>82</sup> although the broad methodological variety (e.g., videos, text, images, gamification strategies, chats with trained therapists or automated bots) in studies of computer-based therapies makes it a challenge to determine which elements are most important and for whom. Both CBT and interpersonal therapy have also been shown to improve mood among adolescents with subthreshold depressive symptoms, but studies have not been able to show whether progression to full MDD is prevented by these interventions. Involvement of caregivers seems to have a better response than therapies focusing only on the adolescent.<sup>83</sup> Although family therapy, mindfulness-based therapies and short-term psychodynamic therapy may be helpful, the evidence supporting their use is more modest than for CBT or interpersonal therapy.<sup>78,84</sup> Dialectical behavioural therapy has shown promising results, specifically in reducing suicidal ideation and nonsuicidal self-injury among adolescents.<sup>59</sup> Acceptance and commitment therapy, a technique that focuses on acknowledging the painful emotions that come with depression as valid, and on creating strategies to move past them, has been garnering interest recently, but at this point, evidence to support its effectiveness is limited.

### Medications

The decision to start antidepressant medication should be made through a collaborative process with the patient and caregivers, taking into account clinical presentation, and after the clinician outlines the range of evidence-based treatment options.<sup>34</sup> Antidepressant medications are recommended for young people with more severe clinical presentations, or in circumstances where psychological therapy is not effective or possible.<sup>34</sup> The risks of pharmacologic therapy should be weighed against those of inadequately treating depression in this vulnerable population.<sup>85</sup> Most clinical guidelines, including the 2019 guideline from the National Institute for Health and Care Excellence in the United Kingdom, recommend initial treatment with psychotherapy only, rather than combined treatment, given the potential adverse effects of medication.<sup>40</sup> Some guidelines suggest trying psychoeducation and lifestyle modifications for 2 weeks, or evidence-based psychotherapies such as CBT or interpersonal therapy for 4–6 sessions, before considering an antidepressant medication.<sup>34,38,40</sup>

Fluoxetine is the first-line medication recommended in most guidelines. A 2020 meta-analysis of RCTs suggested that only fluoxetine plus CBT or fluoxetine alone were more efficacious than placebo and other interventions for youth with depression.<sup>86</sup> Randomized controlled trials evaluating other selective serotonin reuptake inhibitors (SSRIs) have shown similar efficacy to fluoxetine, but discrepant response rates to placebo, suggesting that the identification of fluoxetine as the only effective SSRI may be an artifact of the varied study designs across SSRI trials.<sup>87,88</sup> Modest evidence supports use of sertraline and escitalopram.<sup>37</sup> Most clinical guidelines recommend at least 2 full SSRI trials before other antidepressant classes are considered, given the limited efficacy data and poorer tolerability of other medication classes among adolescents.<sup>88</sup> Fluoxetine is

usually started at 10 mg/d and increased after 1 week to 20 mg/d, and may require 2–6 weeks for positive effects to be noted. The largest RCT of fluoxetine for treatment of MDD among youth showed a number needed to treat of 4 for response (defined as very much improved or much improved on the Clinical Global Impression-Improvement scale) over the first 12 weeks.<sup>89</sup> If fluoxetine is not well tolerated or efficacious, clinicians should consider pharmacokinetics and tolerability when choosing a different SSRI that has some, albeit more modest, evidence for efficacy in adolescent depression (e.g., sertraline, escitalopram). Prescribers should regularly assess clinical response and optimize the SSRI dose as needed and tolerated, with the goal of achieving full symptomatic remission.<sup>90</sup> Patients who do respond well to SSRIs usually experience a gradual improvement of their symptoms, with relatively mild adverse effects that resolve as treatment progresses. Once full remission is achieved, treatment with an SSRI should continue at the therapeutic dosage for at least another 6–12 months before considering a slow taper.

Antidepressant exposure has been associated with an increased risk of suicidal ideation and behaviour in about 2% of young people with depression, particularly during the first few weeks of treatment.<sup>91</sup> Clinicians should discuss these risks with patients and caregivers before starting medication, with consideration that untreated depression is itself a major risk factor for suicide.

Mild gastrointestinal effects are common during the first 4 weeks of treatment, and usually resolve by week 8.<sup>92</sup> Transient insomnia can be managed by taking the medication in the morning.<sup>92</sup> Activation symptoms like jitteriness, restlessness or anxiety may occur early in treatment if the titration is too rapid.<sup>92</sup>

Complementary and alternative medicines are not recommended by current guidelines.<sup>34,40</sup> Preliminary data are promising for St. John's wort and, to a lesser extent, S-adenosylmethionine and 5-hydroxytryptophan.<sup>93</sup> However, studies of these agents have tended to be small or uncontrolled when compared with studies of lifestyle modifications. Adverse effects and drug interactions should be noted; St. John's wort induces the activity of enzymes in the cytochrome P450 family (CYP3A4, CYP2D9 and CYP2C19), making drugs such as oral contraceptives, warfarin, cyclosporin and indinavir less effective. Preparations can vary greatly in quality and content of active ingredients (hypericin and hyperforin), making it challenging to optimize dosing and manage adverse effects.<sup>93</sup>

If patients with MDD do not respond adequately to treatment, it is advisable to revisit the differential diagnosis and consider referral. Specialist support is required for adolescents presenting with acute safety concerns, for complex presentations including symptoms consistent with bipolar disorder and for patients not responding to first-line treatment (Box 2).

## Conclusion

Depression is an increasingly common but treatable condition among adolescents. Primary care physicians and pediatricians are well positioned to support the assessment and first-line management of depression in this group, helping patients to regain their health and function. Future research that addresses important clinical questions in the detection and treatment of adolescent depression is needed (Box 3).

### Box 2: When to refer to psychiatry or other specialized care

- Diagnostic clarification, particularly for patients with concern for
  - Psychotic features
  - Hypomania or mania
- Comorbidities affecting diagnosis and treatment (e.g., substance use, trauma, autism spectrum disorder, other neurodevelopmental disorders)
- Suicidal or homicidal behaviour, or acute safety concerns
- Severe functional impairment or psychosocial stressors
- Treatment nonresponse or serious adverse effects of treatment
- Recurrent or persistent depression
- Management of comorbid psychiatric disorders that are not responding to treatment

### Box 3: Unanswered questions

- What are the differential impacts of the COVID-19 pandemic on prevalence of depressive disorders among subgroups of children and youth in Canada?
- Does screening for depression in primary care and school settings lead to improved outcomes?
- How can lifestyle interventions be used most effectively to improve depressive symptoms?
- What patient, family and treatment factors affect outcomes of selective serotonin reuptake inhibitors, psychotherapy and combination treatments?

## References

1. Liu Q, He H, Yang J, et al. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. *J Psychiatr Res* 2020;126:134-40.
2. Avenevoli S, Swendsen J, He JP, et al. Major depression in the national comorbidity survey — adolescent supplement: prevalence, correlates, and treatment. *J Am Acad Child Adolesc Psychiatry* 2015;54:37-44.e2.
3. Georgiades K, Duncan L, Wang L, et al. Six-month prevalence of mental disorders and service contacts among children and youth in Ontario: evidence from the 2014 Ontario Child Health Study. *Can J Psychiatry* 2019;64:246-55.
4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published erratum in *Arch Gen Psychiatry* 2005;62:T68]. *Arch Gen Psychiatry* 2005;62:593-602.
5. Green C, Leyenaar JK, Turner AL, et al. Competency of future pediatricians caring for children with behavioral and mental health problems. *Pediatrics* 2020 Jul;146(1):e20192884.
6. Data and Statistics on Children's Mental Health. Atlanta: Centers for Disease Control and Prevention; 2023. Available: <https://www.cdc.gov/childrensmentalhealth/data.html> (accessed 2023 Mar. 9).
7. Lu W. Adolescent depression: national trends, risk factors, and healthcare disparities. *Am J Health Behav* 2019;43:181-94.
8. Racine N, McArthur BA, Cooke JE, et al. global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis. *JAMA Pediatr* 2021;175:1142-50.
9. Korczak DJ, Goldstein BI. Childhood onset major depressive disorder: course of illness and psychiatric comorbidity in a community sample. *J Pediatr* 2009;155:118-23.
10. Goldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2015;132:965-86.
11. Goodman SH. Intergenerational transmission of depression. *Annu Rev Clin Psychol* 2020;16:213-38.

12. Lipsky RK, McDonald CC, Souders MC, et al. Adverse childhood experiences, the serotonergic system, and depressive and anxiety disorders in adulthood: a systematic literature review. *Neurosci Biobehav Rev* 2022;134:104495.
13. van Dijk MT, Murphy E, Posner JE, et al. Association of multigenerational family history of depression with lifetime depressive and other psychiatric disorders in children: results from the Adolescent Brain Cognitive Development (ABCD) Study. *JAMA Psychiatry* 2021;78:778-87.
14. Ono Y, Ando J, Onoda N, et al. Dimensions of temperament as vulnerability factors in depression. *Mol Psychiatry* 2002;7:948-53.
15. Lefkovic E, Baji I, Rigo J. Impact of maternal depression on pregnancies and on early attachment. *Infant Ment Health J* 2014;35:354-65.
16. Sahle BW, Reavley NJ, Li W, et al. The association between adverse childhood experiences and common mental disorders and suicidality: an umbrella review of systematic reviews and meta-analyses. *Eur Child Adolesc Psychiatry* 2022;31:1489-99.
17. Kingsbury M, Sucha E, Manion I, et al. Adolescent mental health following exposure to positive and harsh parenting in childhood. *Can J Psychiatry* 2020;65:392-400.
18. Russell ST, Fish JN. Mental health in lesbian, gay, bisexual, and transgender (LGBT) youth. *Annu Rev Clin Psychol* 2016;12:465-87.
19. Grunin L, Yu G, Cohen S. Combined race and gender trend disparities in depressive symptoms among US high school students: 1999-2019. *Issues Ment Health Nurs* 2022;43:824-34.
20. *Diagnostic and statistical manual of mental disorders*. Fifth Edition, Text Revision ed. Washington (D.C.): American Psychiatric Association; 2022.
21. Cicchetti D, Toth SL. The development of depression in children and adolescents. *Am Psychol* 1998;53:221-41.
22. Jaycox LH, Stein BD, Paddock S, et al. Impact of teen depression on academic, social, and physical functioning. *Pediatrics* 2009;124:e596-605.
23. Matza LS, Revicki DA, Davidson JR, et al. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. *Arch Gen Psychiatry* 2003;60:817-26.
24. Ryan ND, Puig-Antich J, Ambrosini P, et al. The clinical picture of major depression in children and adolescents. *Arch Gen Psychiatry* 1987;44:854-61.
25. Rice F, Riglin L, Lomax T, et al. Adolescent and adult differences in major depression symptom profiles. *J Affect Disord* 2019;243:175-81.
26. Dunlap LJ, Orme S, Zarkin GA, et al. Screening and intervention for suicide prevention: a cost-effectiveness analysis of the ED-SAFE interventions. *Psychiatr Serv* 2019;70:1082-7.
27. Wolff JC, Thompson E, Thomas SA, et al. Emotion dysregulation and non-suicidal self-injury: a systematic review and meta-analysis. *Eur Psychiatry* 2019;59:25-36.
28. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011;168:1266-77.
29. Kwong ASF, Lopez-Lopez JA, Hammerton G, et al. Genetic and environmental risk factors associated with trajectories of depression symptoms from adolescence to young adulthood. *JAMA Netw Open* 2019;2:e196587.
30. Final recommendation statement: depression in children and adolescents: screening. Rockville (MD): United States Preventive Services Task Force; 2019. Available: <https://www.uspreventiveservicestaskforce.org> (accessed 2022 June 1).
31. Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. practice preparation, identification, assessment, and initial management. *Pediatrics* 2018;141:e20174081. doi: 10.1542/peds.2017-4081.
32. Cheung AH, Zuckerbrot RA, Jensen PS, et al.; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. treatment and ongoing management. *Pediatrics* 2018;141:e20174082. doi: 10.1542/peds.2017-4082.
33. Birmaher B, Brent D, AACAP Work Group on Quality Issues; Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry* 2007;46:1503-26.
34. Walter HJ, Abright AR, Bukstein OG, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. [Epub ahead of print]. *J Am Acad Child Adolesc Psychiatry* 2022 Oct. 21;S0890-8567(22)01852-4. doi: 10.1016/j.jaac.2022.10.001.
35. APA clinical practice guideline for the treatment of depression across three age cohorts. Washington (D.C.) American Psychological Association; 2019. Available: <https://www.apa.org/depression-guideline> (accessed 2022 May 16).
36. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. special populations: youth, women, and the elderly. *Can J Psychiatry* 2016;61:588-603.
37. Korczak DJ; Canadian Paediatric Society, Mental Health and Developmental Disabilities Committee. Suicidal ideation and behaviour. *Paediatr Child Health* 2015;20:257-64.
38. Korczak DJ; Canadian Paediatric Society, Mental Health and Developmental Disabilities Committee. Use of selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness. *Paediatr Child Health* 2013;18:487-91.
39. MacMillan HL, Patterson CJ, Wathen CN, et al. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. *CMAJ* 2005;172:33-5.
40. Depression in children and young people: identification and management (NG134) [guideline]. London (UK): National Institute for Health and Care Excellence; 2019. Available: <https://www.nice.org.uk/guidance/ng134> (accessed 2022 May 16).
41. Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry* 2021;55:7-117.
42. Siu AL, Force USPST. Screening for depression in children and adolescents: US Preventive Services Task Force recommendation statement. *Pediatrics* 2016;137:e20154467.
43. Yan M, Chen L, Yang M, et al. Evidence mapping of clinical practice guidelines recommendations and quality for depression in children and adolescents. *Eur Child Adolesc Psychiatry* 2022 Mar 9. doi: 10.1007/s00787-022-01958-z. [Epub ahead of print].
44. AGREE-II user's manual. AGREE Next Steps Consortium; 2013. Available: <https://www.agreertrust.org> (accessed 2022 June 7).
45. Bennett K, Courtney D, Duda S, et al. An appraisal of the trustworthiness of practice guidelines for depression and anxiety in children and youth. *Depress Anxiety* 2018;35:530-40.
46. Duda S, Fahim C, Szatmari P, et al. Is the National Guideline Clearinghouse a trustworthy source of practice guidelines for child and youth anxiety and depression? *J Can Acad Child Adolesc Psychiatry* 2017;26:86-97.
47. Beck A, LeBlanc JC, Morissette K, et al. Screening for depression in children and adolescents: a protocol for a systematic review update. *Syst Rev* 2021;10:24.
48. Nandakumar AL, Vande Voort JL, Nakonezny PA, et al. Psychometric properties of the Patient Health Questionnaire-9 modified for major depressive disorder in adolescents. *J Child Adolesc Psychopharmacol* 2019;29:34-40.
49. Radloff LS. The CES-D scale: a self-report report depression scale for research in the general population. *Appl Psychol Meas* 1977;1:385-401.
50. Wood A, Kroll L, Moore A, et al. Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. *J Child Psychol Psychiatry* 1995;36:327-34.
51. Krause KR, Chung S, Adewuya AO, et al. International consensus on a standard set of outcome measures for child and youth anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder. *Lancet Psychiatry* 2021;8:76-86.
52. Osman A, Kopper BA, Barrios F, et al. Reliability and validity of the Beck depression inventory-II with adolescent psychiatric inpatients. *Psychol Assess* 2004;16:120-32.
53. Kovacs M. Rating scales to assess depression in school-aged children. *Acta Paedopsychiatr* 1981;46:305-15.
54. Mangione CM, Barry MJ, Nicholson WK, et al. US Preventive Services Task Force. Screening for depression and suicide risk in children and adolescents: USPSTF recommendation statement. *JAMA* 2022;328:1534-42.
55. Wahid SS, Ottman K, Hudhud R, et al. Identifying risk factors and detection strategies for adolescent depression in diverse global settings: a Delphi consensus study. *J Affect Disord* 2021;279:66-74.
56. Pinquart M, Shen Y. Depressive symptoms in children and adolescents with chronic physical illness: an updated meta-analysis. *J Pediatr Psychol* 2011;36:375-84.
57. Duffy A, Goodday S, Keown-Stoneman C, et al. The emergent course of bipolar disorder: observations over two decades from the Canadian High-Risk Offspring cohort. *Am J Psychiatry* 2019;176:720-9.
58. O'Donovan C, Alda M. Depression preceding diagnosis of bipolar disorder. *Front Psychiatry*. 2020;11:500.
59. Mehlum L, Tormoen AJ, Ramberg M, et al. Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. *J Am Acad Child Adolesc Psychiatry* 2014;53:1082-91.
60. Faedda GL, Serra G, Marangoni C, et al. Clinical risk factors for bipolar disorders: a systematic review of prospective studies. *J Affect Disord* 2014;168:314-21.
61. Kendler KS, Ohlsson H, Sundquist J, et al. Family genetic risk scores and the genetic architecture of major affective and psychotic disorders in a Swedish national sample. *JAMA Psychiatry* 2021;78:735-43.
62. Diler RS, Goldstein TR, Hafeman D, et al. Characteristics of depression among offspring at high and low familial risk of bipolar disorder. *Bipolar Disord* 2017; 19:344-52.

63. Goldstein BI, Shamseddeen W, Axelson DA, et al. Clinical, demographic, and familial correlates of bipolar spectrum disorders among offspring of parents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 2010;49:388-96.
64. Egger HL, Costello EJ, Erkanli A, et al. Somatic complaints and psychopathology in children and adolescents: stomach aches, musculoskeletal pains, and headaches. *J Am Acad Child Adolesc Psychiatry* 1999;38:852-60.
65. Gonzalez A, Boyle MH, Kyu HH, et al. Childhood and family influences on depression, chronic physical conditions, and their comorbidity: findings from the Ontario Child Health Study. *J Psychiatr Res* 2012;46:1475-82.
66. Merikangas KR, Calkins ME, Burstein M, et al. Comorbidity of physical and mental disorders in the neurodevelopmental genomics cohort study. *Pediatrics* 2015;135:e927-38.
67. Malas N, Plioplys S, Pao M. Depression in medically ill children and adolescents. *Child Adolesc Psychiatr Clin N Am* 2019;28:421-45.
68. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007;370:851-8.
69. Sanford M, Boyle M, McCleary L, et al. A pilot study of adjunctive family psychoeducation in adolescent major depression: feasibility and treatment effect. *J Am Acad Child Adolesc Psychiatry* 2006;45:386-495.
70. Orlando L, Savel KA, Madigan S, et al. Dietary patterns and internalizing symptoms in children and adolescents: a meta-analysis. *Aust N Z J Psychiatry* 2022;56:617-41.
71. Campisi SC, Krause KR, Chan BWC, et al. Eating, sleeping and moving recommendations in clinical practice guidelines for paediatric depression: umbrella review. *BJPsych Open* 2021;7:e185.
72. Bailey AP, Hetrick SE, Rosenbaum S, et al. Treating depression with physical activity in adolescents and young adults: a systematic review and meta-analysis of randomised controlled trials. *Psychol Med* 2018;48:1068-83.
73. Korczak DJ, Madigan S, Colasanto M. children's physical activity and depression: a meta-analysis. *Pediatrics* 2017;139:e20162266..
74. Chekroud SR, Gueorguieva R, Zheutlin AB, et al. Association between physical exercise and mental health in 1.2 million individuals in the USA between 2011 and 2015: a cross-sectional study. *Lancet Psychiatry* 2018;5:739-46.
75. Korczak DJ, Perruzza S, Chandrapalan M, et al. The association of diet and depression: an analysis of dietary measures in depressed, non-depressed, and healthy youth. *Nutr Neurosci* 2022;25:1948-55.
76. Firth J, Marx W, Dash S, et al. The effects of dietary improvement on symptoms of depression and anxiety: a meta-analysis of randomized controlled trials. *Psychosom Med* 2019;81:265-80.
77. Popper CW. Mood disorders in youth: exercise, light therapy, and pharmacologic complementary and integrative approaches. *Child Adolesc Psychiatr Clin N Am* 2013;22:403-41, v.
78. Méndez J, Sanchez-Hernandez O, Garber J, et al. Psychological treatments for depression in adolescents: more than three decades later. *Int J Environ Res Public Health* 2021;18:4600.
79. Wergeland GJH, Riise EN, Ost LG. Cognitive behavior therapy for internalizing disorders in children and adolescents in routine clinical care: a systematic review and meta-analysis. *Clin Psychol Rev* 2021;83:101918.
80. Kunas SL, Lautenbacher LM, Lueken PU, et al. Psychological predictors of cognitive-behavioral therapy outcomes for anxiety and depressive disorders in children and adolescents: a systematic review and meta-analysis. *J Affect Disord* 2021;278:614-26.
81. Duffy F, Sharpe H, Schwannauer M. Review: the effectiveness of interpersonal psychotherapy for adolescents with depression — a systematic review and meta-analysis. *Child Adolesc Ment Health* 2019;24:307-17.
82. Wickersham A, Barack T, Cross L, et al. Computerized cognitive behavioral therapy for treatment of depression and anxiety in adolescents: systematic review and meta-analysis. *J Med Internet Res* 2022;24:e29842.
83. Dippel N, Szota K, Cuijpers P, et al. Family involvement in psychotherapy for depression in children and adolescents: a systematic review and meta-analysis. *Psychol Psychother* 2022;95:656-79.
84. Reangsing C, Punsuwun S, Schneider JK. Effects of mindfulness interventions on depressive symptoms in adolescents: a meta-analysis. *Int J Nurs Stud* 2021;115:103848.
85. Murphy SE, Capitao LP, Giles SLC, et al. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. *Lancet Psychiatry* 2021;8:824-35.
86. Zhou X, Teng T, Zhang Y, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020;7:581-601.
87. Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. *Am J Psychiatry* 2017;174:430-7.
88. Strawn JR, Walkup JT. Identifying the best treatment for young people with depression. *Lancet Psychiatry* 2020;7:562-3.
89. Dwyer JB, Bloch MH. Antidepressants for pediatric patients. *Curr Psychiatry* 2019;18:26-42F.
90. Dwyer JB, Stringaris A, Brent DA, et al. Annual research review: defining and treating pediatric treatment-resistant depression. *J Child Psychol Psychiatry* 2020;61:312-32.
91. Li K, Zhou G, Xiao Y, et al. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. *Front Psychiatry* 2022;13:880496.
92. Strawn JR, Mills JA, Poweleit EA, et al. Adverse effects of antidepressant medications and their management in children and adolescents. *Pharmacotherapy* 2023 Jan. 18. doi: 10.1002/phar.2767. [Epub ahead of print].
93. Kenda M, Kocevar Glavac N, Nagy M, et al. Medicinal plants used for anxiety, depression, or stress treatment: an update. *Molecules* 2022;27:6021.

**Competing interests:** Daphne Korczak reports funding from the Canadian Institutes of Health Research (CIHR), SickKids Foundation, University of Toronto and Ontario Ministry of Health, and travel support from the Canadian Paediatric Society and the Canadian Academy of Child and Adolescent Psychiatry. She is chair of the Mental Health Task Force with the Canadian Paediatric Society and of the Research and Scientific Program Committee with the Canadian Academy of Child and Adolescent Psychiatry. Clara Westwell-Roper reports funding from the International OCD Foundation, BC Children's Hospital Research Institute and the University of British Columbia Department of Psychiatry. Roberto Sassi reports funding from CIHR, Juravinski Research Institute and Hamilton

Health Sciences, and travel support from the Provincial Health Services Authority. No other competing interests were declared.

This article has been peer reviewed.

**Affiliations:** Department of Psychiatry (Korczak), Hospital for Sick Children; Department of Psychiatry (Korczak), Temerty Faculty of Medicine, University of Toronto, Toronto, Ont.; Department of Psychiatry (Westwell-Roper, Sassi), Faculty of Medicine, University of British Columbia, Vancouver, BC

**Contributors:** All authors contributed to the conception and design of the article, and to interpretation of the relevant literature. All authors drafted the manuscript, revised it

critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

**Content licence:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>

**Correspondence to:** Daphne Korczak, [daphne.korczak@sickkids.ca](mailto:daphne.korczak@sickkids.ca)